Fate Therapeutics Q4: cash $205M, OpEx down 30%, FT819 outpatient treatment milestone

FATE THERAPEUTICS INC

2025-FY EPS reported -$1.15 vs consensus -$0.28 ▼ miss (-318.0%)

Cash and investments $205.1M as of Dec 31, 2025; operating runway through year-end 2027.
Q4 revenue $1.4M from Ono collaboration; total operating expenses $36.1M (R&D $25.4M, G&A $10.7M).
FT819 off-the-shelf CAR T: 15 SLE, 4 SSc, 1 IIM patients treated; outpatient same-day discharge achieved.
FT836 (Sword & Shield) in CRC: first patient shows >50% CEA reduction and tumor shrinkage at DL1 without conditioning chemo.
Operating expenses reduced 30% in 2025 vs 2024; common shares 115.4M, pre-funded warrants 3.9M, preferred 2.8M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.